172 related articles for article (PubMed ID: 17649793)
1. Prognostic importance of thymidine kinase in colorectal and breast cancer.
Svobodova S; Topolcan O; Holubec L; Treska V; Sutnar A; Rupert K; Kormunda S; Rousarova M; Finek J
Anticancer Res; 2007; 27(4A):1907-9. PubMed ID: 17649793
[TBL] [Abstract][Full Text] [Related]
2. Changes of serum thymidine kinase in children with acute leukemia.
Votava T; Topolcan O; Holubec L; Cerna Z; Sasek L; Finek J; Kormunda S
Anticancer Res; 2007; 27(4A):1925-8. PubMed ID: 17649797
[TBL] [Abstract][Full Text] [Related]
3. EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols.
Span P; Heuvel J; Romain S; Piffanelli A; Martin PM; Geurts-Moespot A; Sweep F
Anticancer Res; 2000; 20(2A):681-7. PubMed ID: 10810340
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
5. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
6. [Clinical application of thymidine kinase activity in patients with acute non-lymphocytic leukemia].
Sampi K; Takagi T; Sakai C; Kuraishi Y; Ishige K
Gan To Kagaku Ryoho; 1991 Jan; 18(1):69-73. PubMed ID: 1987902
[TBL] [Abstract][Full Text] [Related]
7. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies.
Liska V; Holubec L; Treska V; Skalicky T; Sutnar A; Topolcan O; Kormunda S; Finek J
Anticancer Res; 2007; 27(4A):1887-91. PubMed ID: 17649789
[TBL] [Abstract][Full Text] [Related]
10. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
11. Serum big endothelin-1 levels in female patients with breast cancer.
Yildirim Y; Gunel N; Coskun U; Sancak B; Bukan N; Aslan S; Cetin A
Int Immunopharmacol; 2008 Aug; 8(8):1119-23. PubMed ID: 18550016
[TBL] [Abstract][Full Text] [Related]
12. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
13. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
14. Soluble intercellular adhesion molecule-1 as a prognostic marker for stage II colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Koike Y; Yokoe T; Tanaka K; Kusunoki M
Ann Surg Oncol; 2008 Jun; 15(6):1617-24. PubMed ID: 18368454
[TBL] [Abstract][Full Text] [Related]
15. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy.
Topolcan O; Holubec L; Finek J; Stieber P; Holdenrieder S; Lamerz R; Holubec Sen L; Svobodova S; Visokai V; Lipska L
Anticancer Res; 2005; 25(3A):1831-3. PubMed ID: 16033109
[TBL] [Abstract][Full Text] [Related]
16. Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients.
El-Awady S; Lithy R; Morshed M; Khafagy W; Abd Monem H; Waleed O; Badr S; Fekry A; El Nakeeb A; Ghazy H; El Yamany M; Metwally T; El-Arman M; Farid M
Hepatogastroenterology; 2009; 56(90):361-6. PubMed ID: 19579599
[TBL] [Abstract][Full Text] [Related]
17. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
[TBL] [Abstract][Full Text] [Related]
18. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
19. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse.
Yie SM; Lou B; Ye SR; Cao M; He X; Li P; Hu K; Rao L; Wu SM; Xiao HB; Gao E
Ann Surg Oncol; 2008 Nov; 15(11):3073-82. PubMed ID: 18670822
[TBL] [Abstract][Full Text] [Related]
20. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
